PARIS--Genset here announced that it has completely sequenced the genomes of two pathogens, Chlamydia pneumoniae, a possible agent for atherosclerosis lesions, and the Chlamydia trachomatis L2 strain. The company said it is applying for patents for both sequences and that it will license out the therapeutic, diagnostic, and vaccine applications of the genomic data to pharmaceutical companies.
The two bacteria infect a large number of eukaryotic cells and are responsible for a wide range of human diseases. "The determination and analysis of the complete sequence of this important pathogen is a clear demonstration of the power and quality of Genset's fully integrated genome analysis platform," claimed Pascal Brandys, Genset's chairman and CEO, about Chlamydia pneumoniae. He added that the sequencing work reinforces Genset's position in cardiovascular genomics research.